Some probiotics have potential as add-on treatment for Parkinson’s

Researchers have identified six probiotic strains that could potentially be used as a supplement to standard Parkinson’s disease treatment. These probiotics, live bacteria commonly used to aid digestion, were studied using fecal samples. The study found that these bacterial strains promoted a healthier gut environment and supported the production of key neurotransmitters, such as GABA and serotonin. The study, published in the Journal of Future Foods, highlights the potential of probiotics to address some limitations of Parkinson’s treatments like levodopa, which increases dopamine levels in the brain. However, less than 10% of levodopa reaches the brain due to its conversion into dopamine in the gut, and it can cause side effects. Probiotics may help mitigate these issues. Parkinson’s has been linked to gut dysbiosis, an imbalance of gut bacteria that causes inflammation. Restoring gut health may help regulate the gut-brain axis, a communication system that affects both gut and brain function. Researchers screened 855 bacterial strains from patients with Parkinson’s, people at risk, and healthy individuals. Of these, 23 met probiotic criteria, with six showing strong potential. These six strains were able to produce neurotransmitters like GABA and serotonin, as well as anti-inflammatory short-chain fatty acids, without interfering with levodopa. The probiotics demonstrated an ability to group together in the gut and form protective barriers against harmful bacteria. The study suggests that these probiotics could help reduce the side effects of Parkinson’s medication, improve drug effectiveness, and enhance patients’ quality of life.